Live Chat

交易 Vir Biotechnology VIR

VirBiotechnology 实时图表

见解

Weekly Search
Weekly
Daily
date 关闭 change 更改(%): 开盘价

Markets.com news

New Zealand dollar drops on unexpected dovish tone from RBNZ
Georgy Istigechev 2024 Jul 10, 10:00

Unexpected dovish tone from RBNZ drops New Zealand dollar

Forex Indices USD
Sterling steady as investors take in UK, French election results
Georgy Istigechev 2024 Jul 09, 10:15

Sterling steady near one-month high in wake of UK election

Forex Indices GBP USD EUR
BP shares fall on Q2 profit warning
Georgy Istigechev 2024 Jul 09, 10:00

BP shares drop over 4% on Q2 lower profit warning

Shares Indices Oil FTSE100
BP shares dip ahead of Powell Congress testimony
Neil Wilson 2024 Jul 09, 07:30

BP dips, Powell Congress speech ahead, records for Tokyo, NY

Shares Indices Forex Commodities

信息

点差

0.05

点差(%)

0.6623 %

杠杆

1:10

隔夜利息(买入)

-0.0597 %

隔夜利息(卖出)

-0.0292 %

币种

USD

交易时间

市场关闭

星期二

14:31 - 20:59

星期一

14:31-20:59

星期三

14:31-20:59

星期四

14:31-20:59

星期五

14:31-20:59

利润表

开盘价

---

昨收

---

52 周高点/低点

--- – ---

市值

1010864832

在外流通股份

137720000

财报日(下一)

0000-00-00

instr__dividend_date

instr__ex_dividend_date

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

每股收益

-3.93

在外流通股份

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

详细了解此金融票据

资产
出售
买入
更改(%):
相关金融票据
Trustpilot
Live Chat